Matteo Lambertini1, Christine Campbell2, José Bines, Larissa A Korde3, Miguel Izquierdo4, Debora Fumagalli5, Lucia Del Mastro6, Michail Ignatiadis1, Kathleen Pritchard7, Antonio C Wolff8, Christian Jackisch9, Istvan Lang10, Michael Untch11, Ian Smith12, Frances Boyle13, Binghe Xu14, Carlos H Barrios15, José Baselga16,17, Alvaro Moreno-Aspitia18, Martine Piccart1, Richard D Gelber19, Evandro de Azambuja1. 1. Department of Medical Oncology, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium. 2. Frontier Science, Kingussie, UK. 3. Breast Cancer Therapeutics, National Cancer Institute, Bethesda, MD. 4. Novartis Pharma AG, Basel, Switzerland. 5. Breast International Group, Brussels, Belgium. 6. Department of Medical Oncology, U.O. Sviluppo Terapie Innovative, Policlinico San Martino-IRCCS per l'Oncologia, Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy. 7. Sunnybrook Odette Cancer Centre, the University of Toronto and the NCIC Clinical Trials Group, Toronto, Ontario, Canada. 8. Johns Hopkins School of Medicine, Baltimore, MD. 9. Department of Gynecology and Obstetrics, Sana Klinikum Offenbach, Offenbach, Germany. 10. National Institute of Oncology, Budapest, Hungary. 11. Helios Klinikum Berlin Buch, Multidisciplinary Breast Cancer Center, Berlin, Germany. 12. Breast Unit, Royal Marsden Hospital and The Institute of Cancer Research, London, UK. 13. Patricia Ritchie Centre for Cancer Care and Research, The University of Sydney, Mater Hospital, North Sydney, Australia. 14. Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China. 15. Department of Medicine, PUCRS, School of Medicine, Porto Alegre, Brazil. 16. Instituto Nacional de Câncer, Rio de Janeiro, Brazil. 17. Memorial Sloan Kettering Cancer Center, New York, NY. 18. Mayo Clinic, Jacksonville, FL. 19. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health and Frontier Science and Technology Research Foundation, Boston, MA.
Abstract
Background: In premenopausal patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, the gonadotoxicity of trastuzumab and lapatinib remains largely uncertain, and the prognostic effect of treatment-related amenorrhea (TRA) is unknown. Methods: In the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (BIG 2-06) phase III trial, HER2-positive early breast cancer patients were randomized (1:1:1:1) to receive one year of trastuzumab, lapatinib, their sequence, or their combination. As per study protocol, menopausal status was collected in all patients at random assignment and at week 37 visit. We investigated TRA rates and whether TRA in patients with hormone receptor-positive and -negative tumors would impact disease-free survival (DFS) and overall survival (OS). Landmark and time-dependent modeling were used to account for guarantee-time bias. All statistical tests were two-sided. Results: A total of 2862 premenopausal women were included, of whom 1679 (58.7%) had hormone receptor-positive disease. Median age was 43 (interquartile range = 38-47) years. Similar TRA rates were observed in the trastuzumab (72.6%), lapatinib (74.0%), trastuzumab→lapatinib (72.1%), and trastuzumab+lapatinib (74.8%) arms (P = .64). The association between TRA and survival outcomes differed according to hormone-receptor status (Pinteraction for DFS = .007; Pinteraction for OS = .003). For hormone receptor-positive patients, the TRA cohort had statistically significantly better DFS (adjusted hazard ratio [aHR] = 0.58, 95% confidence interval [CI] = 0.45 to 0.76) and OS (aHR = 0.63, 95% CI = 0.40 to 0.99) than the no TRA cohort. No difference was observed in hormone receptor-negative patients. Conclusions: In this unplanned analysis, no association between TRA rate and type of anti-HER2 treatment was observed. TRA was associated with statistically significant survival benefits in premenopausal hormone receptor-positive/HER2-positive early breast cancer patients.
RCT Entities:
Background: In premenopausal patients with humanepidermal growth factor receptor 2 (HER2)-positive early breast cancer, the gonadotoxicity of trastuzumab and lapatinib remains largely uncertain, and the prognostic effect of treatment-related amenorrhea (TRA) is unknown. Methods: In the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (BIG 2-06) phase III trial, HER2-positive early breast cancerpatients were randomized (1:1:1:1) to receive one year of trastuzumab, lapatinib, their sequence, or their combination. As per study protocol, menopausal status was collected in all patients at random assignment and at week 37 visit. We investigated TRA rates and whether TRA in patients with hormone receptor-positive and -negative tumors would impact disease-free survival (DFS) and overall survival (OS). Landmark and time-dependent modeling were used to account for guarantee-time bias. All statistical tests were two-sided. Results: A total of 2862 premenopausal women were included, of whom 1679 (58.7%) had hormone receptor-positive disease. Median age was 43 (interquartile range = 38-47) years. Similar TRA rates were observed in the trastuzumab (72.6%), lapatinib (74.0%), trastuzumab→lapatinib (72.1%), and trastuzumab+lapatinib (74.8%) arms (P = .64). The association between TRA and survival outcomes differed according to hormone-receptor status (Pinteraction for DFS = .007; Pinteraction for OS = .003). For hormone receptor-positive patients, the TRA cohort had statistically significantly better DFS (adjusted hazard ratio [aHR] = 0.58, 95% confidence interval [CI] = 0.45 to 0.76) and OS (aHR = 0.63, 95% CI = 0.40 to 0.99) than the no TRA cohort. No difference was observed in hormone receptor-negative patients. Conclusions: In this unplanned analysis, no association between TRA rate and type of anti-HER2 treatment was observed. TRA was associated with statistically significant survival benefits in premenopausal hormone receptor-positive/HER2-positive early breast cancerpatients.
Authors: F A Peccatori; H A Azim; R Orecchia; H J Hoekstra; N Pavlidis; V Kesic; G Pentheroudakis Journal: Ann Oncol Date: 2013-06-27 Impact factor: 32.976
Authors: Kathryn J Ruddy; Shari I Gelber; Rulla M Tamimi; Elizabeth S Ginsburg; Lidia Schapira; Steven E Come; Virginia F Borges; Meghan E Meyer; Ann H Partridge Journal: J Clin Oncol Date: 2014-02-24 Impact factor: 44.544
Authors: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: Alison W Loren; Pamela B Mangu; Lindsay Nohr Beck; Lawrence Brennan; Anthony J Magdalinski; Ann H Partridge; Gwendolyn Quinn; W Hamish Wallace; Kutluk Oktay Journal: J Clin Oncol Date: 2013-05-28 Impact factor: 44.544
Authors: Patricia A Ganz; Stephanie R Land; Charles E Geyer; Reena S Cecchini; Joseph P Costantino; Eduardo R Pajon; Louis Fehrenbacher; James N Atkins; Jonathan A Polikoff; Victor G Vogel; John K Erban; Robert B Livingston; Edith A Perez; Eleftherios P Mamounas; Norman Wolmark; Sandra M Swain Journal: J Clin Oncol Date: 2011-02-07 Impact factor: 50.717
Authors: Sandra M Swain; Jong-Hyeon Jeong; Charles E Geyer; Joseph P Costantino; Eduardo R Pajon; Louis Fehrenbacher; James N Atkins; Jonathan Polikoff; Victor G Vogel; John K Erban; Priya Rastogi; Robert B Livingston; Edith A Perez; Eleftherios P Mamounas; Stephanie R Land; Patricia A Ganz; Norman Wolmark Journal: N Engl J Med Date: 2010-06-03 Impact factor: 176.079
Authors: Nikita M Shah; Dana M Scott; Pridvi Kandagatla; Molly B Moravek; Erin F Cobain; Monika L Burness; Jacqueline S Jeruss Journal: Ann Surg Oncol Date: 2019-01-24 Impact factor: 5.344
Authors: Patricia A Ganz; Reena S Cecchini; Louis Fehrenbacher; Charles E Geyer; Priya Rastogi; John P Crown; Michael P Thirlwell; David M Ellison; Jean-Francois Boileau; Patrick J Flynn; Jong-Hyeon Jeong; Eleftherios P Mamounas; Norman Wolmark Journal: NPJ Breast Cancer Date: 2021-05-20
Authors: Valentino Martelli; Maria Maddalena Latocca; Tommaso Ruelle; Marta Perachino; Luca Arecco; Kristi Beshiri; Maria Grazia Razeti; Marco Tagliamento; Maurizio Cosso; Piero Fregatti; Matteo Lambertini Journal: Breast Cancer (Dove Med Press) Date: 2021-05-24
Authors: Wanyuan Cui; Prudence A Francis; Sherene Loi; Martha Hickey; Catharyn Stern; Lumine Na; Ann H Partridge; Sibylle Loibl; Richard A Anderson; Karla J Hutt; Louise A Keogh; Kelly-Anne Phillips Journal: J Natl Cancer Inst Date: 2021-05-28 Impact factor: 11.816